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Summary
Laparoscopy is usually undertaken in young women with adnexal disease that is believed to be benign, but found to 
be malignant at surgery. Some surgeons use laparascopy for staging, but mainly for presumed stage I or II ovarian cancer. 
Also, laparoscopy can be useful for selecting women who can be optimally debulked at primary surgery. There are some 
concerns about using laparoscopic approach in women with ovarian cancer: port-site metastasis, possibility of intraopera-
tive rupture of tumor and eff ect of pneumoperitoneum. Studies showed that rate of port-site metastasis after laparoscopic 
surgery in women with ovarian cancer is low and usually occurs when there is peritoneal carcinomatosis or distant meta-
static disease. Also, it seems that laparoscopy with CO(2) pneumoperitoneum does not reduce the overall survival in  women 
with intraabdominal metastases. Preoperative rupture, surface capsular invasion and positive peritoneal cytology are more 
relevant in terms of prognosis than intraoperative rupture, but further research is needed. Conventional laparoscopy and 
robotic-assisted laparoscopy are comparable in both early and advanced disease. These approaches are not inferior to lapa-
rotomy and they are acceptable access in selected patients.
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ULOGA LAPAROSKOPIJE U LIJEČENJU RAKA JAJNIKA
Sažetak
Laparoskopija se najčešće koristi kod žena za koje se mislilo da imaju benignu bolest, ali se tijekom operacije isposta-
vilo da se radi o malignoj bolesti. Neki kirurzi koriste laparoskopski pristup za stupnjevanje bolesti i to najčešće za pretpo-
stavljeni I ili II stadij. Također, laparoskopija može biti korisna za odabir žena kojima se može primarno napraviti „debul-
king“. Postoji nekoliko briga prilikom korištenja laparoskopskog pristupa: pojava metastaza na mjestu ulaska troakara, 
mogućnost intraoperacijske rupture tumora i učinak pneumoperitoneuma. Studije su pokazale da je udio metastaza na 
mjestu ulaska troakara nizak i da se najčešće javlja kod žena koje imaju karcinomatozu peritoneuma i udaljene metastaze. 
Također, čini se da laparoskopija s CO2 pneumoperitoneumom ne smanjuje ukupno preživljenje žena s intraabdominalnim 
metastazama. Preoperacijska ruptura, površinska invazija kapsule i pozitivan peritonealni ispirak su važniji za prognozu od 
intraoperacijske rupture, no daljnja istraživanja su potrebna. Konvencionalna i laparoskopija pomoću robota su usporedive 
i u ranoj i u proširenoj bolesti.Ovi pristupi nisu inferiorni laparotomiji i prihvatljivi su kod odabranih pacijenata.
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INTRODUCTION
An adnexal mass can be found in women of 
all ages. It can be discovered on routine pelvic ex-
amination or because of pelvic pain,  pressure or 
any other symptom. The biggest concern is the 
possibility that it is malignant. In premenopausal 
women the overall risk of malignancy of adnexal 
mass is 6 to 11 percent and 29 to 35 percent in post-
menopausal women (1). Suspicion of malignancy 
of an adnexal mass is the appearance of the mass 
on imaging study. Society of Radiologists in Ultra-
sound (SRU) indicated that transvaginal ultra-
sound is bett er technique for imaginig and charac-
terizing an adnexal mass than a transabdominal 
ultrasound (2). Some ultrasound morphology are 
associated with malignancy, like a solid compo-
nent or nodularity, color Doppler positive fl ow in 
the solid component and septations (>2 to 3 mm). 
Pelvic ultrasound has 86 to 91 percent sensitivity 
for the diagnosis of ovarian cancer and the speci-
fi city ranged from 68 to 83 percent (3).  
SURGICAL TREATMENT
For woman with suspicious mass, surgical 
evaluation is the standard approach becauseovar-
ian cancer can not be diagnosed with noninvasive 
technique. Many women undergoing surgery for 
a benign mass because of this approach. Buys SS 
et al.(4) showed in their large randomized trial 
that among 570 women who underwent surgical 
evaluation for suspected ovarian cancer, 20 cases 
of malignancy were found. However, the risk for 
failing to diagnose ovarian cancer must be weighed 
against the potential morbidity of surgery. 
LAPAROSCOPY IN OVARIAN CANCER 
TREATMENT
Laparoscopy is usually undertaken in young 
women with adnexal disease that is believed to be 
benign, but found to be malignant at surgery. 
Some surgeons use laparascopy for staging, but 
mainly for presumed stage I or II ovarian cancer. 
Park HJ et al. (5) founded no diff erence between 
laparoscopy and laparotomy in operative dura-
tion in women with presumed stage I or II ovarian 
cancer. Except the fact that laparoscopic surgery 
was associated with less blood loss. Only 3.7 per-
cent was converted in to laparotomy. Also, lapa-
roscopy can be useful for selecting women who 
can be optimally debulked at primary surgery. 
Fagott i et al. (6,7) investigated the role of laparos-
copy in predicting optimal cytoreduction  in pa-
tients with advanced ovarian cancer.  In their 
study, 113 women with a preoperative diagnosis 
of stage III or IV ovarian cancer underwent diag-
nostic laparoscopy followed by laparotomy with 
staging and cytoreduction (6). Some features like 
omental cake, peritoneal and diaphragmatic carci-
nosis,  bowel and stomach infi ltration, spleen and 
liver metastasiscan be discovered by diagnostic 
laparoscopy  and predict whether optimal cytore-
duction could be accomplished. Because surfaces 
cannot be palpated laparoscopically, question is 
whether the pelvis and abdomen can beexamined 
as closely as with an open surgery. Data from 
some studies proposed that the stage assigned 
laparoscopically does not vary from laparotomy 
(8, 9).
Another concern by using a laparoscopy ap-
proach to remove a suspicious adnexal mass is 
fear of rupture of tumor capsule and dissemina-
tion of malignant cells. Performing oophorectomy 
rather than a cystectomy, if ovarian cancer is sus-
pected, and use of a laparoscopic bag is the best 
way to avoid an intraperitoneal spillage (10). Co-
pious irrigation should be performedif rupture 
happens. How rupture of an ovarian capsule af-
fects on prognosis is arguable (11,12).  The possi-
ble mechanism of dissemination of malignant cells 
after rupture is through the peritoneal circulation 
(13). Preoperative rupture, surface capsular inva-
sion and positive peritoneal cytology are more rel-
evant in terms of prognosis than intraoperative 
rupture, but further research is needed. Kim HS et 
al. (14) found a signifi cantly worse progression-
free survival related with preoperative extracap-
sular disease compared with intraoperative rup-
ture or no rupture in few studies that included 
only women with complete surgical staging and 
adjuvant chemotherapy. Bakkum-Gamez JN et al. 
(15) showed that  intraoperative capsule rupture 
and positive cytologic washings are predictors of 
worse disease-free survival.Also, intraoperative 
capsule rupture announce a higher risk of disease 
recurrence.However, still is not clear whether 
worse prognosis related with intraoperative rup-
ture is due to rupture or to a missed diagnosis of 
advanced disease in incompletely staged women.
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Other concern for  using  laparoscopy as a 
method in women with malignant disease is port 
site metastasis. The rate of port-site metastasis af-
ter laparoscopic surgery in women with ovarian 
cancer is low and usually occurs when there is 
peritoneal carcinomatosis or distant metastatic 
disease (16). Because of that, Zivanovic O et al. 
(16) considered that port-site tumor implantation 
should not be used as an argument against laparo-
scopic approach in treatment of ovarian cancer. 
Some other studies disagree. Morice P et al. (17) 
proposed to avoid port-site metastasis andso-
women with an evidently malignant ovarian tu-
mor should not be treated laparoscopically. 
It is questionable how pneumoperitoneum in 
laparoscopic approach aff ectson the survival of 
women with persistent metastatic ovarian cancer. 
Abu-Rustum NR et al.(18) described the survival 
of women with stage III-IV ovarian cancer as doc-
umented by positive second-look laparoscopy or 
laparotomy. They concluded that laparoscopy 
with CO(2) pneumoperitoneum does not appear 
to reduce the overall survival in women with in-
traabdominal metastases.
ROBOTICS IN OVARIAN 
CANCER SURGERY
Some clinical centers are using the da Vinci 
robotic surgical system. Brown JV 3rd et al. (19) 
founded a low incidence of lymph node meta-
stases and suitable  readmission rate by using ro-
botic-assisted surgical staging. They retrospec-
tively reviewed the charts of presumed early-stage 
ovarian cancer patients who underwent robotic-
assisted surgery which included a pelvic and pa-
ra-aortic lymphadenectomy. There was no in-
traoperative and postoperative complications. 
However, they suggested that surgeons should 
consider a systematic lymph node resection to 
 advise a best clinical evaluation, because the prev-
alence of aff ected lymph node can approach 20% 
in select patients. Nezhat FR et al. (20) founded 
that perioperative outcomes are comparable be-
tween conventional laparoscopy and robotic-as-
sisted laparoscopy in both early and advanced 
disease. These approaches are not inferior to lapa-
rotomy and they are acceptable access in selected 
patients.
CONCLUSION
Laparoscopic surgery is acceptable access in 
selected patients. It is associated with a faster re-
covery and decreased perioperative morbidity 
compared with laparotomy. Further studies are 
needed to confi rmed equivalence between laparo-
scopic surgery and laparotomy in women with 
ovarian cancer.
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